.png){kind=icon}
.png){kind=icon}
Return
Postbiotics and Mental Health: A New Frontier in Mood Disorders
.png){kind=icon}
PRE
AI
H
H
A
M
B
A
DOI：10.1177/1934578X261433104.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Mood disorders are increasingly recognized as systemic conditions involving immune dysregulation and gut-brain axis disturbances. While probiotics and prebiotics have been extensively studied, the mechanistic and therapeutic roles of postbiotics-the bioactive metabolites produced by microorganisms-remain insufficiently synthesized in psychiatric research. This review addresses this gap by examining how key postbiotic compounds, including short-chain fatty acids (SCFAs), gamma-aminobutyric acid (GABA), serotonin, dopamine, tryptophan metabolites, and oxytocin, modulate neuroimmune pathways implicated in depression and related disorders. Mechanistically, postbiotics influence histone deacetylase activity, G-protein-coupled receptor signaling, cytokine production, microglial activation, and blood-brain barrier integrity. Emerging clinical data suggest adjunctive benefits in stress, anxiety, and depressive symptoms, though dose-response relationships and long-term outcomes remain underexplored. Overall, postbiotics represent a promising mechanistically targeted strategy for modulating the gut-brain-immune axis; however, rigorous clinical trials are required to validate therapeutic efficacy and optimize formulation and dosing strategies.
Keywords:
Anxiety
depression
gut microbiota
mania
mental disorders
postbiotics
probiotics
psychosis
Journal
N
IF:
1.4
Papers:
188
Citations:
7.8K
Organization
Cited Papers